The virtual synapse and its contribution to understanding cholinergic neurotransmission;La synapse virtuelle: Quel apport pour la compréhension de la neurotransmission?

Therapie

Volumn 59, Issue 1, 2004, Pages 21-23

  Geerts, Hugo ^a  

^a In Silico Biosciences   (United States)

Author keywords

Alzheimer; Dopamine; Mathematical modelling; Synapse

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DOPAMINE; GALANTAMINE; GLUTAMIC ACID; NICOTINIC RECEPTOR; NORADRENALIN; SEROTONIN;

ALZHEIMER DISEASE; CHOLINERGIC TRANSMISSION; CHOLINESTERASE INHIBITION; CONFERENCE PAPER; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; MATHEMATICAL MODEL; NEUROANATOMY; NEUROPHARMACOLOGY; NEUROTRANSMISSION; PRIORITY JOURNAL; SYNAPSE; VALIDATION PROCESS;

EID: 2942682680     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2004005     Document Type: Conference Paper

References (5)

1. Durstewitz J, Seaman J, Sejnowski T. Dopamine-mediated stabilisation of delay-period activity in a network model of the prefrontal cortex. J Neurophysiology 2000; 183: 1733-50
2. Geerts H, Spiros A, Lazarewicz M, et al. Galantamine benefits in Alzheimer's disease are related to increases in dopamine output. Schizophrenia Res 2003; 60: S135
3. Geerts H, Finkel L, Carr R, et al. Nicotinic receptor modulation: advantages for successful Alzheimer's disease therapy. Journal of Neural Transmission 2002; Suppl. 62: 203-16
4. Greengard P. The neurobiology of slow synaptic transmission. Science 2000; 294: 1024-30
5. Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003; 20 (10): 777-89